In conclusion, our work identifies FAP as an excellent marker of CMS4 CRC, including peritoneal metastases, and suggests that FAPI-PET is a promising tool for its comprehensive detection, thus generating a quantitative measure of ‘CMS4-load’ in cancer patients, which may form a basis for patient selection. This evidence concerns the gene FAP and cancer.